Whites Have Longest Survival in Cutaneous Melanoma

Share this content:
Whites Have Longest Survival in Cutaneous Melanoma
Whites Have Longest Survival in Cutaneous Melanoma

FRIDAY, Oct. 28, 2016 (HealthDay News) -- For patients with cutaneous melanoma, whites have the longest survival time, according to a study published in the November issue of the Journal of the American Academy of Dermatology.

Sean M. Dawes, M.P.H., from the Michigan State University College of Osteopathic Medicine in East Lansing, and colleagues examined survival across racial groups in patients with malignant melanoma. Data were included from the Surveillance, Epidemiology, and End Results database for 96,953 patients with a diagnosis of cutaneous melanoma as their primary cancer from 1992 to 2009.

The researchers found that white patients had the longest survival time, followed by Hispanic, Asian-American/Native-American/Pacific-Islander, and black patients. After stratification by race and stage, blacks had significantly lower survival for stages I and III (P < 0.05), with increased hazard ratios of 3.037 and 1.864, respectively. Compared with whites, blacks had a greater proportion of later-stage cutaneous melanoma.

"Despite higher incidence of cutaneous melanoma in whites, overall survival for cutaneous melanoma in non-whites was significantly lower," the authors write. "Our results suggest that more emphasis is needed for melanoma screening and awareness in non-white populations to improve survival outcome."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »